Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ODT's Cash-to-Debt is ranked higher than
60% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ODT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ODT' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
ODT's Interest Coverage is ranked higher than
50% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ODT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ODT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 14.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -48.55
ODT's ROE % is ranked lower than
54% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ODT: -48.55 )
Ranked among companies with meaningful ROE % only.
ODT' s ROE % Range Over the Past 10 Years
Min: -257.73  Med: -200.04 Max: -48.55
Current: -48.55
-257.73
-48.55
ROA % -45.81
ODT's ROA % is ranked lower than
60% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ODT: -45.81 )
Ranked among companies with meaningful ROA % only.
ODT' s ROA % Range Over the Past 10 Years
Min: -204.24  Med: -158.55 Max: -45.81
Current: -45.81
-204.24
-45.81
ROC (Joel Greenblatt) % -9983.54
ODT's ROC (Joel Greenblatt) % is ranked lower than
89% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ODT: -9983.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ODT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44071.43  Med: -44071.43 Max: -9983.54
Current: -9983.54
-44071.43
-9983.54
GuruFocus has detected 1 Warning Sign with Odonate Therapeutics Inc ODT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ODT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ODT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Odonate Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:AMAG, TSE:2160, NAS:ACIU, NAS:ABEO, NAS:CHRS, NAS:RCKT, TSE:7774, XKRX:084110, TSE:3034, NAS:OMER, SZSE:002286, NAS:LJPC, NAS:VYGR, NAS:ANIP, SZSE:300381, HKSE:00775, NAS:NVAX, SZSE:300705, XBRU:TIG, NAS:DCPH » details
Traded in other countries:4OD.Germany,
Headquarter Location:USA
Odonate Therapeutics Inc is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel an chemotherapy agent used in the treatment of cancer.

Odonate Therapeutics Inc is a US-based pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. The key product of the company is Tesetaxel which is a chemotherapy for oral administration with a low pill burden for various types of cancers.

Top Ranked Articles about Odonate Therapeutics Inc

Weekly CEO Buys Highlight Details the CEO buys this past week from the following companies: Odonate Therapeutics, Elanco Animal Health, Y-mAbs Therapeutics, Tallgrass Energy and Neogen
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
Weekly CEO Buys Highlight Details the CEO buys this past week from the following companies: Odonate Therapeutics, Bausch Health Companies, FGL Holdings, Washington Prime Group and First Bancorp
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
Weekly CEO Buys Highlight Details the CEO buys this past week from the following companies: Odonate Therapeutics, Arcus Biosciences, Erie Indemnity, Essential Properties and Apple Hospitality REIT
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
New Research: Key Drivers of Growth for Helen of Troy, Macro Bank, American Software, Shire plc, KB Financial Group, and Odonate Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
Largest Insider Trades of the Week T-Mobile, Odonate on the list
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “February 2018” and All Insider Sales to “$5,000,000+.” Read more...
Weekly CEO Buys Highlight Details the CEO buys this past week for the following companies: Odonate Therapeutics, W. R. Grace & Co., Gaming and Leisure Properties, AT&T and OPKO
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.51
ODT's PB Ratio is ranked higher than
61% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ODT: 2.51 )
Ranked among companies with meaningful PB Ratio only.
ODT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 298.47
Current: 2.51
0
298.47
EV-to-EBIT -2.82
ODT's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ODT: -2.82 )
Ranked among companies with meaningful EV-to-EBIT only.
ODT' s EV-to-EBIT Range Over the Past 10 Years
Min: -220.29  Med: 0 Max: 0.84
Current: -2.82
-220.29
0.84
EV-to-EBITDA -2.83
ODT's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ODT: -2.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
ODT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -220.29  Med: 0 Max: 0.84
Current: -2.83
-220.29
0.84
Current Ratio 10.89
ODT's Current Ratio is ranked higher than
89% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ODT: 10.89 )
Ranked among companies with meaningful Current Ratio only.
ODT' s Current Ratio Range Over the Past 10 Years
Min: 4.79  Med: 17.56 Max: 27.02
Current: 10.89
4.79
27.02
Quick Ratio 10.89
ODT's Quick Ratio is ranked higher than
89% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ODT: 10.89 )
Ranked among companies with meaningful Quick Ratio only.
ODT' s Quick Ratio Range Over the Past 10 Years
Min: 4.79  Med: 17.56 Max: 27.02
Current: 10.89
4.79
27.02

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.60
ODT's Price-to-Net-Cash is ranked higher than
78% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ODT: 2.60 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ODT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.6  Med: 3.55 Max: 3.58
Current: 2.6
2.6
3.58
Price-to-Net-Current-Asset-Value 2.56
ODT's Price-to-Net-Current-Asset-Value is ranked higher than
78% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ODT: 2.56 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ODT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 3.47 Max: 3.52
Current: 2.56
2.56
3.52
Price-to-Tangible-Book 2.51
ODT's Price-to-Tangible-Book is ranked higher than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ODT: 2.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ODT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.51  Med: 3.44 Max: 3.46
Current: 2.51
2.51
3.46
Earnings Yield (Greenblatt) % -35.50
ODT's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ODT: -35.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ODT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -61.18  Med: 0 Max: 119.05
Current: -35.5
-61.18
119.05

More Statistics

EPS (TTM) $ -3.05
52-Week Range $14.04 - 32.00
Shares Outstanding (Mil)26.83

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}